1University of Pittsburgh School of Medicine.
2Department of Neurological Surgery, University of Pittsburgh Medical Center; and.
J Neurosurg. 2018 Jan;128(1):193-201. doi: 10.3171/2016.9.JNS161022. Epub 2017 Feb 10.
OBJECTIVE Hemifacial spasm (HFS) is a movement disorder characterized by involuntary spasms of the facial muscles, and it can negatively impact quality of life (QOL). This retrospective study and systematic review with meta-analysis was conducted to investigate the QOL in patients with HFS following intervention with microvascular decompression (MVD) and botulinum toxin (BT). METHODS In the retrospective analysis, a QOL questionnaire was administered to all patients undergoing MVD performed by a single surgeon. The QOL questionnaire included unique questions developed based on the authors' experience with HFS patients in addition to the health-related QOL HFS-8 questionnaire. The authors also report on a systematic review of the English literature providing outcomes and complications in patients with HFS undergoing treatment with either MVD or BT. RESULTS Regarding the retrospective analysis, 242 of 331 patients completed the questionnaire. The mean score of the 10 QOL questions improved from 22.78 (SD 9.83) to 2.17 (SD 5.75) following MVD (p < 0.001). There was significant improvement across all subscales of the questionnaire between pre- and postoperative responses (p < 0.001). Regarding the systematic review, it is reported that approximately 90% of patients undergoing MVD for HFS experience a complete recovery from symptoms, whereas the mean peak improvement of symptoms following treatment with BT is 77%. Furthermore, patients undergoing MVD reported a greater improvement in the mean supplemental index of QOL as compared with patients receiving BT therapy. CONCLUSIONS Microvascular decompression offers a significant improvement in QOL in well-selected patients suffering from HFS, and may offer an increased benefit for QOL over BT injections.
面肌痉挛(HFS)是一种以面部肌肉不自主痉挛为特征的运动障碍,会对生活质量(QOL)产生负面影响。本回顾性研究和系统评价结合荟萃分析旨在调查接受微血管减压术(MVD)和肉毒毒素(BT)治疗后面肌痉挛患者的 QOL。
在回顾性分析中,对由一位外科医生进行 MVD 的所有患者进行 QOL 问卷调查。QOL 问卷包括根据作者在 HFS 患者方面的经验开发的独特问题,以及与健康相关的 HFS-8 问卷。作者还报告了一项英语文献系统评价,该评价提供了接受 MVD 或 BT 治疗的 HFS 患者的结局和并发症。
关于回顾性分析,331 名患者中有 242 名完成了问卷。MVD 后,10 个 QOL 问题的平均评分从 22.78(SD 9.83)改善至 2.17(SD 5.75)(p<0.001)。问卷的所有子量表在术前和术后反应之间均有显著改善(p<0.001)。关于系统评价,报告称约 90%接受 MVD 治疗 HFS 的患者症状完全缓解,而 BT 治疗后症状的平均峰值改善率为 77%。此外,与接受 BT 治疗的患者相比,接受 MVD 的患者报告了 QOL 补充指数的更大改善。
微血管减压术为患有 HFS 的精选患者提供了 QOL 的显著改善,并且可能比 BT 注射提供更高的 QOL 获益。